Compare MAA & SLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MAA | SLRX |
|---|---|---|
| Founded | 1977 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.3B | 3.6M |
| IPO Year | 1994 | N/A |
| Metric | MAA | SLRX |
|---|---|---|
| Price | $132.11 | $0.79 |
| Analyst Decision | Buy | |
| Analyst Count | 20 | 0 |
| Target Price | ★ $155.30 | N/A |
| AVG Volume (30 Days) | ★ 907.6K | 664.7K |
| Earning Date | 02-04-2026 | 11-14-2025 |
| Dividend Yield | ★ 4.59% | N/A |
| EPS Growth | ★ 6.34 | N/A |
| EPS | ★ 4.71 | N/A |
| Revenue | ★ $2,203,402,000.00 | N/A |
| Revenue This Year | $1.82 | N/A |
| Revenue Next Year | $2.24 | N/A |
| P/E Ratio | $28.03 | ★ N/A |
| Revenue Growth | ★ 0.92 | N/A |
| 52 Week Low | $125.75 | $0.71 |
| 52 Week High | $173.38 | $108.00 |
| Indicator | MAA | SLRX |
|---|---|---|
| Relative Strength Index (RSI) | 48.38 | 26.49 |
| Support Level | $131.32 | $0.81 |
| Resistance Level | $133.72 | $0.89 |
| Average True Range (ATR) | 2.02 | 0.07 |
| MACD | -0.14 | 0.10 |
| Stochastic Oscillator | 31.30 | 8.25 |
Mid-America Apartment Communities Inc or MAA, is a real estate investment trust engaged in the acquisition, operation, and development of multifamily apartment communities located in the southeastern and southwestern United States. The company operates two reportable segments; Same Store includes communities that the Company has owned and have been stabilized for at least a full 12 months as of the first day of the calendar year and Non-Same Store and Other includes recently acquired communities, communities being developed or in lease-up, communities that have been disposed of or identified for disposition, communities that have experienced a casualty loss and stabilized communities that do not meet the requirements to be Same Store communities.
Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.